A small difference in the molecular structure of angiotensin II receptor blockers induces at 1 receptor-dependent and-independent beneficial effects

Hypertension Research

Volumn 33, Issue 10, 2010, Pages 1044-1052

  Fujino, Masahiro ^a   Miura, Shin Ichiro ^a,b   Kiya, Yoshihiro ^a   Tominaga, Yukio ^c   Matsuo, Yoshino ^a   Karnik, Sadashiva S ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

angiotensin II type 1 receptor blocker; insurmountability; inverse agonism; molecular structure; monocyte chemoattractant protein 1

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL PHOSPHATE; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYL GROUP; TYROSINE;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; HYPERTENSION; INVERSE AGONISM; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR GENE;

3T3-L1 CELLS; ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHEMOKINE CCL2; COS CELLS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HEK293 CELLS; HUMANS; KIDNEY; LOSARTAN; MICE; NF-KAPPA B; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 77957699101     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.135     Document Type: Article

References (39)

1. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin- aldosterone system. Nat Rev Drug Discov 2002; 1: 621-636.
2. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115-121.
3. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86.
4. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, Tatematsu S, Wakino S, Saruta T. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875-880.
5. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS, Park GS, Kang WC, Ahn TH, Shin EK. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-1435.
6. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, Tomita S, Uehara Y, Karnik SS, Yanagisawa H, Koike H, Komuro I, Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281: 19288-19295.
7. Soudijn W, van Wijngaarden I, Ijzerman AP. Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev 2005; 25: 398-426.
8. Rossier O, Abuin L, Fanelli F, Leonardi A, Cotecchia S. Inverse agonism and neutral antagonism at alpha(1a)-and alpha(1b)-adrenergic receptor subtypes. Mol Pharmacol 1999; 56: 858-866.
9. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003; 305: 846-853.
10. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
11. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
12. Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 1999; 274: 7103-7110.
13. Tamori Y, Masugi J, Nishino N, Kasuga M. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002; 51: 2045-2055.
14. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2A crystal structure. J Mol Biol 2004; 342: 571-583.
15. Tiziano T, Vincenzo C, Simona R, Adriano M. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006; 49: 4305-4316.
16. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000; 9: 1753-1773.
17. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, Karnik SS. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270: 2284-2289.
18. Takezako T, Gogonea C, Saad Y, Noda K, Karnik SS. 'Network leaning' as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem 2004; 279: 15248-15257.
19. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, Imaizumi S, Fujino M, Ito K, Zou Y, Fukuhara S, Kunimoto S, Fukuzaki K, Sato T, Ge J, Mochizuki N, Nakaya H, Saku K, Komuro I. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9: 179-186.
20. Feng YH, Miura S, Husain A, Karnik SS. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry 1998; 37: 15791-15798.
21. Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 1996; 35: 16435-16442.
22. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
23. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3: 1.
24. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000; 295: 226-232.
25. Engelhardt S, Grimmer Y, Fan GH, Lohse MJ. Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol Pharmacol 2001; 60: 712-717.
26. Spiegel AM. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 1996; 58: 143-170.
27. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649-651.
28. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, Karnik SS, Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139-146.
29. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
30. Schwarz M, Wahl M, Resch K, Radeke HH. IFNgamma induces functional chemokine receptor expression in human mesangial cells. Clin Exp Immunol 2002; 128: 285-294.
31. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DC. Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor kappaB in proximal tubule cells. J Am Soc Nephrol 1999; 10: 1204-1213.
32. Esteban V, Ruperez M, Sánchez-López E, Rodr?́guez- Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, Ruiz-Ortega M. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 2005; 96: 965-973.
33. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
34. Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, Yamamoto R, Miura SI, Saku K, Komuro I. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens Res 2009; 32: 875-883.
35. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
36. Yamada S, Ano N, Toda K, Kitaoka A, Shiono K, Inoue G, Atsuda K, Irie J. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-606.
37. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108: 96-100.
38. Pool JL, Guthrie RM, Littlejohn III TW, Raskin P, Shephard AM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470.
39. Krämer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Böger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776.